The Investigator, Daniel K. Benjamin, Jr., MD, PhD, MPH, will prepare pediatricians for a career in clinical research that uses rigorous quantitative methods. Historically, 75% of drug products have insufficient labeling information needed for pediatric dosing, safety or efficacy. Dr. Benjamin's long-term research goal is to improve pediatric drug development by establishing proper dosing, safety, and efficacy of drugs used in adolescents, children, toddlers, infants, and neonates.
The specific aims are to prepare trainees fora career in acadmic medicine in one of: 1) clinical pharmacology;2) epidemiology and translational research;or 3) biostatistics and clinical trials. In order to fulfill these aims, fellows in the quantitative research methods program obtain formal training in biostatistics, epidemiology, or pharmacology and complete a Masters or PhD degree during their fellowship and first 24 months as faculty. Dr. Benjamin's research plan includes the multisite NICHD-sponsored protocol """"""""Meropenem Pediatric Off-Label Drug Study"""""""" and the proposed """"""""Antimicrobial Pharmacokinetics in High Risk Infants II"""""""" study. Dr. Benjamin also serves as Protocol Chair for 5 protocols sponsored through public-private partnerships between the National Institutes of Health and pharmaceutical industry. Strengths of his program include ongoing funding and active participation in several areas of neonatal pharmacology and therapeutics, including his role as Principal Investigator of the NICHD-sponsored North Carolina Collaborative Pediatric Pharmacology Research Unit (PPRU) site. The North Carolina PPRU ts a collaboration between Duke Pediatrics (Benjamin: PI) and the University of North Carolina School of Pharmacy (Thakker: co-Pi), which serves as a platform for training pediatricians in clinical pharmacology. Dr. Benjamin has formal training and a proven publication record in epidemiology and biostatistics. His expertise in these fields is further demonstrated by his leadership role directing pediatric quantitative analyses within the NCRR-sponsored Duke Clinical and Translational Science Award (CTSA). Feasibility of this program is shown by a proven track record in publications (58 peer-reviewed articles and abstracts) for which trainees are first author, and by the 16 trainees who are enrolled in or have completed masters or PhD degrees in health sciences, epidemiology, biostatics, or pharmacology. These research projects and institutional initiatives made possible by the Duke CTSA and Dr. Benjamin's collaboration with University of North Carolina combine perfectly with his role as Chief of the Division of Quantitative Sciences in the Department of Pediatrics at Duke University, and Fellowship Director of the Duke Clinical Research Institute

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24HD058735-05
Application #
8488453
Study Section
Pediatrics Subcommittee (CHHD)
Program Officer
Higgins, Rosemary
Project Start
2009-07-01
Project End
2014-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
5
Fiscal Year
2013
Total Cost
$149,380
Indirect Cost
$11,065
Name
Duke University
Department
Other Clinical Sciences
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Maharaj, Anil R; Gonzalez, Daniel; Cohen-Wolkowiez, Michael et al. (2018) Improving Pediatric Protein Binding Estimates: An Evaluation of ?1-Acid Glycoprotein Maturation in Healthy and Infected Subjects. Clin Pharmacokinet 57:577-589
Shakhnovich, Valentina; Smith, P Brian; Guptill, Jeffrey T et al. (2018) Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures. J Pediatr 193:102-108.e1
Gray, Keyaria D; Dudash, Kathryn; Escobar, Carla et al. (2018) Prevalence and safety of diazoxide in the neonatal intensive care unit. J Perinatol 38:1496-1502
Rivera-Chaparro, Nazario D; Ericson, Jessica; Wu, Huali et al. (2018) Safety, Effectiveness, and Exposure-Response of Micafungin in Infants: Application of an Established Pharmacokinetics Model to Electronic Health Records. Pediatr Infect Dis J :
Kumar, Karan R; Clark, David A; Kim, Evan M et al. (2018) Association of Atrial Septal Defects and Bronchopulmonary Dysplasia in Premature Infants. J Pediatr 202:56-62.e2
Watt, Kevin M; Avant, Debbie; Sherwin, Jennifer et al. (2018) Effect of renal function on antihypertensive drug safety and efficacy in children. Pediatr Nephrol 33:139-146
Le, Jennifer; Poindexter, Brenda; Sullivan, Janice E et al. (2018) Comparative Analysis of Ampicillin Plasma and Dried Blood Spot Pharmacokinetics in Neonates. Ther Drug Monit 40:103-108
Smith, Michael J; Gonzalez, Daniel; Goldman, Jennifer L et al. (2017) Pharmacokinetics of Clindamycin in Obese and Nonobese Children. Antimicrob Agents Chemother 61:
Wynn, James L; Kelly, Matthew S; Benjamin, Daniel K et al. (2017) Timing of Multiorgan Dysfunction among Hospitalized Infants with Fatal Fulminant Sepsis. Am J Perinatol 34:633-639
Ku, Lawrence C; Zimmerman, Kanecia; Benjamin, Daniel K et al. (2017) Safety of Enalapril in Infants Admitted to the Neonatal Intensive Care Unit. Pediatr Cardiol 38:155-161

Showing the most recent 10 out of 140 publications